G1 Therapeutics

204 articles about G1 Therapeutics

• G1 Therapeutics Granted New Technology Add-On Payment (NTAP) for COSELA™ (Trilaciclib) by Centers for Medicare & Medicaid Services (CMS)

  8/4/2021

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced that the Centers for Medicare & Medicaid Services (CMS) has granted a new technology add-on payment (NTAP) for COSELA™ (trilaciclib) when administered to Medicare beneficiaries in the hospital inpatient setting. It will become effective for provider billing on October 1, 2021.

• G1 Therapeutics Announces Appointment of Andrew Perry as Chief Commercial Officer

  8/2/2021

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the appointment of Andrew Perry as its Chief Commercial Officer.

• G1 Therapeutics to Provide Second Quarter 2021 Financial Results and Business Update on August 4, 2021

  7/28/2021

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the second quarter of 2021 on Wednesday, August 4, 2021 at 4:30 p.m. ET.

• G1 Therapeutics Receives Fast Track Designation from U.S. Food and Drug Administration for COSELA™ (Trilaciclib) in Combination with Chemotherapy for the Treatment of Locally Advanced or Metastatic Triple Negative Breast Cancer

  7/19/2021

  G1 Therapeutics, Inc. today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to COSELA™ (trilaciclib) investigation for use in combination with chemotherapy for the treatment of locally advanced or metastatic triple negative breast cancer (TNBC).

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - July 02, 2021

  7/2/2021

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 80,400 shares of G1’s common stock to eight employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• 

  Clinical Catch-Up: June 14-18

  6/21/2021

  It was another busy week of clinical trial announcements. Here’s a look.

• G1 Therapeutics Announces Addition of Alicia Secor to Board of Directors

  6/18/2021

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today announced the appointment of Alicia Secor to its Board of Directors

• G1 Therapeutics to Present at the 2021 Raymond James Human Health Innovation Conference

  6/16/2021

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced that G1’s Chief Executive Officer Jack Bailey will participate in the 2021 Raymond James Human Health Innovation Conference.

• G1 Therapeutics Initiates PRESERVE 3, A Randomized Phase 2 Study of COSELA™ (trilaciclib) in Bladder Cancer

  6/14/2021

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced that the Company has initiated PRESERVE 3, a Phase 2, randomized, open-label study of COSELA™ administered with first-line platinum-based chemotherapy and the immune checkpoint inhibitor avelumab maintenance therapy in patients with untreated, locally advanced or metastatic urothelial carcinoma.

• 

  Clinical Catch-Up: June 7-11

  6/14/2021

  A busy week for clinical trial news as the ASCO meeting wrapped up and the European Hematology Association 2021 Virtual Congress began. Read on for more.

• G1 Therapeutics Presents Phase 1 Data at ASCO Describing Favorable Safety Profile and Evidence of Antitumor Activity of Rintodestrant Combined with Palbociclib in Patients with ER+/HER2- Advanced Breast Cancer

  6/4/2021

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from its Phase 1 study of its oral selective estrogen receptor degrader (SERD), rintodestrant

• G1 Therapeutics Presents Data on COSELA™ (trilaciclib) at ASCO on Potential Immune Activation in Patients with Newly Diagnosed Extensive-Stage Small Cell Lung Cancer

  6/4/2021

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today presented results from analyses evaluating the immune effects of trilaciclib in patients with extensive-stage small cell lung cancer (ES-SCLC) following two Phase 2 clinical trials

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - June 04, 2021

  6/4/2021

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 44,200 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics Announces Upcoming Data at the American Society of Clinical Oncology (ASCO) Virtual 2021 Annual Meeting

  5/19/2021

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced upcoming data presentations at the American Society of Clinical Oncology annual meeting, being held virtually June 4th through 8th.

• G1 Therapeutics Presents Two Posters at ISPOR Describing the Estimated Economic Impact of Treating Myelosuppression Among Patients with Extensive-Stage Small Cell Lung Cancer

  5/17/2021

  Myelosuppression Poses a Substantial Burden on the Health Care System Among Patients with Small Cell Lung Cancer, According to an Analysis of SEER-Medicare Data

• G1 Therapeutics Initiates Randomized Double Blind Placebo Controlled Phase 2 Study of COSELA™ (trilaciclib) in Non-Small Cell Lung Cancer (PRESERVE 4)

  5/10/2021

  PRESERVE 4 Will Evaluate the Survival and Myeloprotection Benefits of COSELA in 146 Patients with Non-Small Cell Lung Cancer (NSCLC) Previously Treated with Checkpoint Inhibitors

• G1 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - May 07, 2021

  5/7/2021

  G1 Therapeutics, Inc., a commercial-stage oncology company, announced the grant of inducement stock options exercisable for an aggregate of 40,000 shares of G1’s common stock to five employees under the G1 Therapeutics, Inc. 2021 Inducement Equity Incentive Plan.

• G1 Therapeutics Provides First Quarter 2021 Financial Results and Operational Highlights

  5/5/2021

  Pivotal Phase 3 Trial of COSELA in Metastatic Triple-Negative Breast Cancer Underway to Evaluate the Survival Benefit of COSELA Compared with Placebo

• 

  Clinical Catch-Up: April 26-30

  5/3/2021

  Although clinical trial news related to COVID-19 was slow last week, there’s quite a bit of news on studies for other indications.

• G1 Therapeutics to Provide First Quarter 2021 Financial Results and Business Update on May 5, 2021

  4/28/2021

  G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, will host a webcast and conference call to provide a corporate and financial update for the first quarter of 2021 on Wednesday, May 5, 2021 at 4:30 p.m. ET.